Biofrontera announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA to expand the indication for Ameluz (aminolevulinic acid hydrochloride) topical gel, 10%, in… read more.
Johnson & Johnson announced new two-year results from the Phase 3 ICONIC-LEAD study evaluating ICOTYDE (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23… read more.
Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced new envudeucitinib data from the ONWARD Phase 3 clinical… read more.
Johnson & Johnson announced new two-year data from the Phase 3 ICONIC-TOTALa study demonstrating the positive impact of ICOTYDE (icotrokinra) on high-impact plaque psoriasis (PsO) sites. ICOTYDE is… read more.
Moberg Pharma AB announced the publication of new analyses demonstrating potent antifungal activity of terbinafine against dermatophytes causing onychomycosis. Importantly, mycological cure with Mob-015 was achieved across the… read more.
Novartis announced that the FDA approved Rhapsido (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for adults with symptomatic dermographism (SD) inadequately controlled… read more.
Eli Lilly and Company announced that the FDA approved Olumiant (baricitinib), a once-daily pill, for the treatment of pediatric patients 12 years of age and older with severe… read more.
Priovant Therapeutics announced the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults… read more.
The first clues that a baby may develop eczema or food allergies could be hiding in the microscopic organisms living on their skin, according to a study led… read more.
Men already at risk genetically for the most common form of hair loss have a 7 percent added risk of losing their hair if they use drugs like… read more.
Knight Therapeutics Inc. announced the launch of Wynzora, a uniform white aqueous cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), in Canada…. read more.
A new study of sunscreens, baby lotions, shampoos, soaps, and other everyday products found that nearly all contained chemicals not disclosed on their labels. Most contained at least one unlabeled… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
